 Edgewise Therapeutics Inc NASDAQ: EWTX posted positive topline results from Phase 1b trial of EDG-5506, designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy DMD and Becker Muscular Dystrophy BMD The seven adults with BMD enrolled in the Phase 1b clinical trial were administered 20 mg oral doses of EDG-5506 n5 or placebo n2. 